Clinical Trial Search

Primary: Average Depression Score Using the Hamilton Depression (HAM-D) 17 Scale — 23.154; 23.076; 13.154; 12.706 units on a scale

Primary: Accuracy in Centimeters From Target Location for Allocentric — 13.24; 15.38; 14.22; 15.03 Centimeters (cm) — p=.048

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12 — -20.39; -59.75 percent change — p=<0.0001

Primary: Peak Plasma Nicotine Concentrations Following Ingestion of a Single (Phase 1) or Repeated (Phase 2) Doses of Nicotine Film — 5.78; 20.5; 8.71; 8.80 ng/mL

Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — -0.84; -64.98 percent change — p=<0.0001

Primary: Area Over Baseline Over 12 Hours (AOB0-12) for the Incisal Bite Force (Positive Control Adhesive Versus [vs.] Negative Control) — 4.78; 2.03 lbs — p=<.0001

Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration — -27.64; -51.71; -72.60; -82.04 Percent change in…

Primary: Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries — 7; 12 days — p=0.002

Primary: Pain Change — 0.53; 1.43 Pre-post NPRS Pain Scale Score

Primary: Cutaneous Tolerance Scores: Erythema — -0.07 Units on a scale

Primary: Participants Self-rating of Pain Using the Wong-Baker FACES Pain Rating Scale. — 42; 38; 6; 8 Participants

Primary: Treatment Success Assessed by IGA — 60.8; 63.2; 56.0 Percentage of Participants — p=0.3520

Primary: Nerve Block Duration — 22.2; 25.7 Hours

Primary: Changes in Smoking-related Gene Expression Signature Score in Nasal Epithelium — -1.11; 1.39 gene expression signature score — p=0.04

Primary: Positive Subscale Score of the Positive and Negative Syndrome Scale (PANSS) — 22; 22.33; 16; 20.33 units on a scale